| |
Cystone,
an indigenous remedy of The Himalaya Drug Company, is mainly indicated
in urinary lithiasis and is said to dissolve urinary calculi. Quite
a few urinary stones are rich in uric acid and the beneficial effects
claimed for Cystone could be due to increased uric acid excretion1.
Gouty
arthritis is characterised by high serum uric acid levels and the
known anti-gout agents bring about relief by uricosuric effect or
by inhibition of uric acid synthesis2,4.
The
objective of this work was to see if Cystone has any beneficial
effect in hyperuricaemic arthritic patients.
Serum uric acid levels were estimated5
in 235 arthritic patients referred by the Orthopaedic Outdoor of
the Sassoon General Hospitals, Pune. Out of these, 90 patients
67 males and 23 females were found to have uric acid levels
higher than 5mg% (the highest in normal range). Detailed clinical
examination of these patients was done and initial score of various
clinical symptoms like pain, tenderness, swelling, restricted joint
movement etc. was recorded by the Orthopaedic Surgeon. Clinical
manifestations were scored according to the severity e.g. severe
pain(++++), moderate pain (+++), bearable pain (++) and mild pain
(+).
Cystone tablets were given in the dose of 2 tablets
3 times a day. Total clinical score of the symptoms for each patient
was recorded initially and then again after 15 days and one month
of Cystone administration. The serum uric acid levels were also
estimated at the same time. However, the clinician only assessed
the clinical improvement or otherwise and was not aware of the uric
acid levels. Likewise, the clinical records were not available to
the workers estimating uric acid levels.
Changes in uric acid levels after 15 days and one
month were compared with the initial value using paired t
tests. At the end of the study, improvement in clinical manifestations
was assessed employing non-parametric tests. Spearmans test
was used to study the correlation between the fall in uric acid
levels and improvement in the clinical pictures.
It
is noteworthy that amongst the arthritics about 38% cases had raised
uric acid levels (90 out of 235). Thirty nine out of these 90 hyperuricaemic
patients did not report for the subsequent studies. Hence, follow-up
was possible with only 51 patients. Only 36 patients could complete
the proposed one months study.
Table
1 shows the classification of these 36 patients on the basis of
their clinical conditions. Fifty per cent cases had osteoarthritis
of the knee joint.
Table
2 shows the changes in uric acid levels and their statistical significance.
|
Table
1: Classification of the patients on the basis of clinical
conditions
|
|
Sl.
No.
|
Clinical
condition
|
No.
of cases
|
|
1.
|
Osteoarthritis
knee |
18
|
|
2.
|
Low
backache |
4
|
|
3.
|
Periarthritis
right shoulder |
1
|
|
4.
|
Cervical
spondylosis |
2
|
|
5.
|
Frozen
right shoulder |
2
|
|
6.
|
Osteoarthritis
spine |
2
|
|
7.
|
Polyarticular
rheumatoid arthritis |
1
|
|
8.
|
Prolapsed
intervertebral disc |
1
|
|
9.
|
Pain
in both heels (Plantar fasciatis) |
3
|
|
10.
|
Pain
in the neck |
1
|
| |
Total
|
36
|
|
Table
2: Mean serum uric acid levels
|
|
No. of patients
|
Mean initial serum uric acid inmg ± SE
|
Mean serum uric acid inmg ± SE after 15 days
|
Mean serum uric acid inmg ± SE after one month
|
|
36
|
5.80
± 0.23
|
5.30
± 0.25
(p<0.05)
|
4.83
± 0.23
(p<0.001)
|
|
51
|
6.008
± 0.18
|
5.51
± 0.23
(p<0.01)
|
|
The
uric acid levels initial, after 15 days and after 30 days
showed a significantly decreasing trend (a=0.001). The total
clinical score of manifestation taken initially and then after 15
days and 30 days also showed a significantly decreasing trend (a=0.001).
However, there is no correlation between the decreasing uric acid
levels and the clinical improvement observed, as judged by the Spearmans
test. Value of R is 6762.5, which is within normal range. (Lower
critical value 5195 Higher critical value 10345).
Disturbance
in uric acid metabolism has been observed in about 38% cases having
arthritic manifestations. Though it is stated that the incidence
of gout in our country is comparatively low, from this study it
would appear that quite a few patients with joint affection have
associated hyperuricaemia (osteoarthritis of knee and the like).
Cystone,
an indigenous tablet preparation of The Himalaya Drug Company, consists
of:
Exts.
Didymocarpus pedicellata 65mg
Saxifraga
ligulata 49mg
Rubia
cordifolia 16mg
Cyperus
scariosus 16mg
Achyranthes
aspera 16mg
Onosma
bracteatum 16mg
Vernonia
cinerea 16mg
Shilajeet
(Purified) 13mg
Hajrul
yahood bhasma 16mg
As
stated by Kirtikar and Basu6 among the ingredients of
Cystone, Rubia cordifolia, Cyperus scariosus, Achyranthes aspera,
Onosma bracteatum, Ocimum basilicum, Tribulus terrestris, Mimosa
pudica, Pavonia odorata and Tectona grandis seeds have analgesic,
antipyretic and anti-inflammatory effects and are as such used in
conditions like lumbago, rheumatism, neuralgia and gouty joints;
whereas rest of the ingredients are mainly used in various urinary
conditions.
From
the results it is clear that administration of Cystone decreases
the raised uric acid levels significantly and also offers significant
improvement in the clinical picture. Though there is no positive
or negative correlation between the fall in uric acid levels and
the clinical improvement, administration of Cystone offers definite
relief to the patients. Thus, Cystone can be used as an adjuvant
in the treatment of various arthritic conditions.
Because
of the significant fall observed in the uric acid levels, administration
of Cystone may be of value in gout also. Once the attack of gout
is brought under control, Cystone may prove useful in maintaining
the uric acid levels low.
Cystone,
an indigenous preparation of The Himalaya Drug Company, has been found
to produce a significant fall in serum uric acid levels and show improvement
in the clinical picture of various arthritic conditions. It can thus
be used in the treatment of gout and also as an adjuvant in the treatment
of various arthritic conditions associated with hyperuricaemia.
- Sengupta, B.R. and Gupta, S., Probe (1978): 3, 279. Cystone
in urinary tract infections.
- Goodman, Louis, S. and Gilman, Alfred, The Pharmacological
Basis of Therapeutics (1975): Vth Ed. Pp. 352-353 and 862-863.
- Talbott, J.H., Proc. Inst. Med., Chicago (1951): 18,
383. Uric acid pool in gout.
- Crone, C. and Lassen, U.V., Acta. Pharmac. Toxica. (1955):
11, 295. Probenacid action on uric acid excretion and plasma uric
acid levels.
- Varley, Harold, Practical Clinical Biochemistry (1969):
IVth Ed., p. 205.
- Kirtikar and Basu, Indian Medical Plants (1933): Vol.
1-4.
|
 |